A Key Opinion Leader strategy for MedTech is not a sponsorship programme. It is a structured way to put your device in the hands of credible clinicians who can tell you the truth about it, shape its development, and later vouch for it to peers — all while staying on the right side of MDR Article 7, which prohibits misleading claims in any promotional material.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • A KOL strategy is how a startup systematically builds relationships with clinicians who shape practice, opinion, and purchasing in a target specialty.
  • Three distinct relationship types exist — advisor, investigator, and payer-facing champion — and each carries different legal, regulatory, and transparency obligations.
  • MDR Article 7 sets the regulatory floor: no claim that misleads the user or patient about the device's intended purpose, safety, or performance, in any promotional material or statement.
  • Structured fair-market-value compensation, written agreements, and transparent disclosures (EFPIA-style for pharma; national MedTech codes for devices) are non-negotiable.
  • Startups that treat KOLs as scientific partners — not as endorsers — get better product feedback, better clinical data, and fewer compliance problems.
  • The Reality Check at the end of this post is the first thing to run before you email your first prospective clinical champion.

Why clinical champions decide whether your device gets used

A founder once told us his product would "sell itself" once hospitals saw it work. Eighteen months post-CE, the device was beautifully engineered, fully documented, reimbursable in two markets — and nobody was using it. The reason was painfully simple. Not a single well-known clinician in the target specialty had ever touched it. Procurement committees in European hospitals do not adopt MedTech on the basis of datasheets. They adopt based on recommendations from clinicians they trust. In most specialties, that group is small, known to each other, and heavily influenced by four or five people per country.

Those people are your KOLs. The question is not whether you need them. The question is whether you build relationships with them early and honestly, or late and desperately.

And because this is MedTech, not consumer software, the way you engage KOLs is constrained by law. MDR Article 7 prohibits misleading claims about a device in labels, instructions for use, promotional materials, and statements — including statements made by third parties where the manufacturer has influence. That means your KOL engagement is never just a commercial activity. It is a regulated activity.

What MDR actually says about promotional content

MDR Article 7 is short and blunt. It prohibits the use of text, names, trademarks, pictures, figurative or other signs that may mislead the user or patient with regard to the device's intended purpose, safety, and performance. It covers labelling, instructions for use, making available, putting into service, and advertising. It applies to what the manufacturer says and, materially, to what the manufacturer causes to be said.

Plain language: if a paid advisor tweets that your Class IIa device "prevents strokes" and the device is cleared for rhythm detection, the manufacturer has a problem under Article 7 regardless of whether the manufacturer wrote the tweet. The claim must match the CE-marked intended purpose. Full stop.

Article 7 is reinforced by national advertising rules — Germany's Heilmittelwerbegesetz (HWG), France's rules on professional promotion, Austria's Arzneimittelgesetz and Medizinproduktegesetz adjacent provisions, and others — and by industry transparency codes. EFPIA's disclosure code is designed for pharma, but MedEurope and national MedTech codes impose similar logic: payments to healthcare professionals must be documented, proportional, and often publicly disclosed.

None of this prevents you from working with clinical champions. All of it shapes how.

Three relationship types, three sets of rules

Advisor. A clinician who gives you scientific input on device design, clinical evaluation, user interface, or clinical workflow. Paid for time, at fair market value, against a written advisory agreement. Output is documented (meeting minutes, advisory board reports). The relationship is confidential where appropriate and disclosed where required. Advisors should not be promoting your device publicly in their advisor capacity — that is a different relationship.

Investigator. A clinician running your clinical investigation under MDR Chapter VI and EN ISO 14155:2020+A11:2024. The relationship is governed by the clinical investigation plan, the contract with the site/sponsor, ethics committee approval, and the regulatory obligations of the sponsor and investigator. Investigators must remain scientifically independent; their job is to generate valid data, not to market the product.

Payer-facing clinical champion. A clinician who helps you make the case to hospital procurement, HTA bodies, or national payers. This is a newer role, less formalised, and the one most likely to slip into Article 7 territory if you are not careful. If you pay them to present at a payer meeting and they overstate performance, you own the consequence.

The Subtract to Ship discipline here is simple: one clinician, one role, one written agreement. Do not let an advisor drift into being an undocumented sales rep. Do not let an investigator drift into being a promoter during the trial. Clarity is kindness — to you, to them, and to the auditor.

A worked example

A Class IIa digital therapeutic startup in Vienna is preparing launch across DACH. The team identifies 14 clinicians across Germany, Austria, and Switzerland who shape practice in the target indication. We sort them.

Four become advisors. They sign advisory agreements at €300 per hour (benchmarked to local fair market value), attend two advisory boards per year, review the clinical evaluation summary before submission, and are explicitly asked not to promote the device on social media during the advisory period. Payments are logged. The startup commits to annual transparency disclosure in line with the national MedTech code.

Three become clinical investigators for the post-market clinical follow-up study. Their relationship is governed entirely by the clinical investigation plan, site contracts, and ethics committee approvals. They receive no "advisory" payments during the trial period. Data flows through the sponsor.

Two become pilot-site clinical champions — they use the device in routine practice at their hospitals, provide anonymised feedback, and are willing to speak at peer events about their clinical experience. The startup provides the device and user support at no charge, in line with a documented pilot agreement. No cash honoraria. The champions speak about their own experience, not manufacturer claims, and the startup briefs them on Article 7 boundaries in writing.

The remaining five clinicians are kept warm for later stages. No payments. Quarterly scientific updates.

Twelve months later, the device has real-world experience from two respected sites, a PMCF dataset under way, an advisory board that has caught two clinical workflow errors before launch, and zero Article 7 exposure. The commercial team has something to sell that is both credible and legally clean.

The Subtract to Ship playbook

Step 1 — Map the 10 clinicians who actually matter. In most European MedTech specialties, the community is small. Identify the clinicians whose opinion moves procurement, who publish, who teach, who sit on guideline panels. Ten is a useful number. Twenty is overkill for most startups.

Step 2 — Sort them by intended role before you contact anyone. Advisor, investigator, champion. Write it down. If a clinician could fill two roles, pick one and be honest about it. Trying to collapse roles is how compliance problems start.

Step 3 — Use one written agreement per role. Advisory agreement, clinical investigation contract, pilot-site agreement. Template these once; never work off email. The contract is cheap insurance.

Step 4 — Benchmark fair market value. Rates vary by country and specialty. Ask a regulatory or compliance lawyer for the local benchmark in your target markets. Pay at fair market value, not above it. Overpayment is the single most common trigger for transparency complaints.

Step 5 — Document outputs. Advisory boards produce minutes. Pilot sites produce feedback reports. Investigators produce investigator reports under the clinical investigation plan. Documentation protects the clinician, the startup, and the data.

Step 6 — Train everyone on Article 7. Any KOL who will speak publicly about your device should get a 30-minute briefing on what they can and cannot say, in writing. Include the current CE-marked intended purpose. Include a few examples of claims that are acceptable and claims that are not.

Step 7 — Disclose. National MedTech transparency codes increasingly expect annual disclosure of payments to healthcare professionals. Check the code in each target market and comply. Transparency is not a burden; it is credibility.

Step 8 — Review quarterly. Relationships drift. Review every KOL relationship every quarter against the original purpose. Close relationships that are not producing value. Escalate ones that are.

Reality Check

  1. Can you name the ten clinicians in your target specialty whose opinion drives adoption in your beachhead market?
  2. Have you assigned each prospective KOL to exactly one role — advisor, investigator, or champion — before first contact?
  3. Do you have a written advisory agreement template reviewed by a local lawyer?
  4. Do you know the fair-market-value hourly rate for clinical advisors in each of your target countries?
  5. Have you briefed every KOL who will speak publicly on MDR Article 7 constraints in writing?
  6. Is there a central log of payments to healthcare professionals, ready for annual disclosure?
  7. Can you explain, in one sentence, how each KOL relationship traces back to your CE-marked intended purpose?
  8. Would an auditor looking at your advisory board minutes and pilot site feedback conclude that the relationships are scientific, not promotional?

Frequently Asked Questions

Can I pay a clinician to promote my device on social media? Paying a clinician to make promotional statements about a specific device is a high-risk construction under MDR Article 7 and most national advertising laws. Statements must match the CE-marked intended purpose, must not mislead, and must be disclosed as paid promotion. Most startups should avoid this entirely and focus on scientific engagement instead.

What is fair market value for an advisor in Europe? It varies by country, specialty, and seniority. Ranges typically fall between €150 and €500 per hour for non-key opinion leaders and higher for senior professors. Ask a local MedTech compliance lawyer for a current benchmark rather than guessing.

Do I have to disclose payments to clinicians? Several national MedTech industry codes in Europe require annual public disclosure of transfers of value to healthcare professionals. Check the code in each target market. Transparency is rapidly becoming the norm.

Is an investigator in our clinical trial also a KOL? They can be, but not at the same time. During the clinical investigation the relationship is governed exclusively by the clinical investigation plan and the sponsor-site contract. Adding a parallel advisory payment during the trial creates a conflict that ethics committees and auditors dislike.

Can a KOL help us with HTA submissions? Yes — clinical champions who understand comparative evidence and can speak to real-world utility are valuable in HTA dossiers. But the relationship still needs a written agreement, fair market compensation, and Article 7 awareness.

What happens if a KOL makes a misleading claim about our device? If the manufacturer paid for the statement, encouraged it, or knew about it and did not correct it, the manufacturer is exposed under Article 7 and national advertising law. Written briefings and written agreements are the cheap prevention.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 7.
  2. MedTech Europe Code of Ethical Business Practice (current version).
  3. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice.